Literature DB >> 16939495

Denis Burkitt and his contribution to haematology/oncology.

Davis Coakley1.   

Abstract

Denis Burkitt was motivated by Christian Evangelism from his early years. It was a critical factor not only in his personal development and decision to work in Uganda, but also in his medical achievements. The events in his life which led to his description of Burkitt lymphoma in 1958 are described together with his discovery of the endemic nature of the condition and its treatment. His research on the aetiology of the condition is also described. The endemic form of the lymphoma is still a major cause of childhood mortality in Africa due to a lack of basic resources to treat the condition. Burkitt Lymphoma has been used as a model to advance research and treatment on a wide range of conditions in haematology and oncology. Burkitt's work in later life on dietary fibre and its implications are summarised.

Entities:  

Mesh:

Year:  2006        PMID: 16939495     DOI: 10.1111/j.1365-2141.2006.06267.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  [Burkitt's and Burkitt-like lymphoma. Molecular definition and value of the World Health Organisation's diagnostic criteria].

Authors:  H Stein; M Hummel
Journal:  Pathologe       Date:  2007-02       Impact factor: 1.011

2.  Is cytotoxic chemotherapy for lymphoma currently feasible for patients in Malawi? A debate.

Authors:  Emma Crutchlow; Yohannie Miombe; Tom Latham
Journal:  Malawi Med J       Date:  2008-12       Impact factor: 0.875

3.  Orbital sporadic Burkitt lymphoma in an adult diabetic African American female and a review of adult orbital cases.

Authors:  John Carmody; Raghunath P Misra; Marlyn P Langford; William A Byrd; Lauren Ditta; Bryan Vekovius; Donald E Texada
Journal:  Clin Ophthalmol       Date:  2011-04-20

Review 4.  Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis.

Authors:  Gary M Hunninghake
Journal:  Thorax       Date:  2019-02-05       Impact factor: 9.139

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.